Alger Health Sciences C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Alger Health Sciences Fund Class C AHSCX
- NAV / 1-Day Return 16.08 / −0.06 %
- Total Assets 68.6M
-
Adj. Expense Ratio
1.960%
- Expense Ratio 1.960%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.00
- Turnover 289%
USD | NAV as of Jul 15, 2026 | 1-Day Return as of Jul 15, 2026, 12:38 AM GMT+0
Morningstar’s Analysis AHSCX
Will AHSCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 35.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Teva Pharmaceutical Industries Ltd ADR | 4.58 | 3M | Healthcare |
Impulse Dynamics Ireland Series F-3 | 4.56 | 3M | — |
Forte Biosciences Inc Ordinary Shares | 4.28 | 3M | Healthcare |
Arrowhead Pharmaceuticals Inc | 4.03 | 2M | Healthcare |
Welltower Inc | 3.22 | 2M | Real Estate |
Cardinal Health Inc | 3.22 | 2M | Healthcare |
Cash | 3.02 | 2M | Cash and Equivalents |
Johnson & Johnson | 2.99 | 2M | Healthcare |
Twist Bioscience Corp | 2.93 | 2M | Healthcare |
Merck & Co Inc | 2.88 | 2M | Healthcare |
United States